RxDoctor Payments DataLook up a doctor →

Mohammed Bari, MD

Psychiatry · National City, CANPI 1679588370

Payments from drug & device makers

$5,773,250in general payments, 2019–2025

Across 1,847 payments — averaging $3125.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$961K
  • Sumitomo Pharma America, Inc.$823K
  • Teva Pharmaceuticals USA, Inc.$706K
  • Sunovion Pharmaceuticals Inc.$550K
  • Hoffmann-la Roche Limited$389K
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$313K
  • plus $2M from 44 others
$79,712in research payments, 2019–2025

Across 10 payments — averaging $7971.15 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Biohaven Pharmaceuticals, Inc.$52K
  • Pfizer$26K
  • Eli Lilly$800

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)224$961,454
Sumitomo Pharma America, Inc.245$822,599
Teva Pharmaceuticals USA, Inc.135$705,918
Sunovion Pharmaceuticals Inc.119$550,233
Hoffmann-la Roche Limited17$388,877
Otsuka Pharmaceutical Development & Commercialization, Inc.8$312,710
Biohaven Pharmaceuticals, Inc.20$307,479
Acadia Pharmaceuticals Inc59$183,630
Biohaven Pharmaceutical Holding Company Ltd.16$180,739
Corcept Therapeutics16$144,143
Roche TCRC, Inc.13$121,227
Sage Therapeutics, LLC26$121,198
Avanir Pharmaceuticals, Inc.21$118,196
Neurocrine Biosciences, Inc.135$117,464
Boehringer Ingelheim12$104,821
Dexcom, Inc.21$101,836
Biogen3$92,428
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)88$86,031
Vertex2$79,257
Pfizer13$78,597
GW Research Limited11$49,274
Alkermes, Inc.154$32,135
American Regent5$27,640
Eisai Inc.21$21,588
Boehringer Ingelheim International GmbH39$12,963
Vanda Pharmaceuticals Inc.55$11,309
Merck3$9,273
Jazz Pharmaceuticals Inc.5$6,217
Boehringer Ingelheim RCV GmbH & Co KG21$6,106
Lexicon Pharmaceuticals, Inc.2$4,500
H. Lundbeck A S1$4,306
Otsuka America Pharmaceutical, Inc.113$2,583
Johnson & Johnson57$1,445
Axsome Therapeutics, Inc.19$1,104
Lundbeck LLC47$947
Eli Lilly6$945
E.r. Squibb & Sons, L.L.C.43$913
Indivior Inc.25$518
Takeda Pharmaceuticals U.S.A., Inc.7$128
CSL Behring1$125
Livanova USA, Inc.4$83
Sun Pharmaceutical Industries Inc.2$69
Idorsia Pharmaceuticals US Inc3$61
Noven Therapeutics, LLC3$49
Novo Nordisk2$34
Luye Pharma (USA) Ltd.1$34
Corium, LLC1$19
Noven Pharmaceuticals, Inc.1$17
Almatica Pharma LLC1$15
GSK1$11

How this compares

$5,773,250 in reported general payments places this provider in the 95th percentile of 4,954 psychiatry providers in California.

See all psychiatry providers in California

Medicare billing

Part B allowed, 2024
$190,456
Medicare patients
415
Services billed
2,282

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other psychiatry in National City

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →